ALK and non-small cell lung carcinoma: In comparison with chemotherapy, the IMpower110, an open-label, randomized phase 3 trial, demonstrated atezolizumab was less toxicity and significantly reduced the risk of disease progression or death by 37% (hazard ratio (HR), 0.63, 95% CI: 0.45-0.88), 33% (HR, 0.67, 95% CI: 0.52-0.88), and 23% (HR, 0.77, 95% CI: 0.63-0.94) for EGFR and ALK wild-type metastatic NSCLC patients who had not previously received chemotherapy with high PD-L1 expression, high or intermediate PD-L1 expression, and any PD-L1 expression, respectively (18).